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ABSTRACT
More efficient therapies that target multiple molecular mechanisms are needed 
for the treatment of incurable bone metastases. Halofuginone is a plant alkaloid-
derivative with antiangiogenic and antiproliferative effects. Here we demonstrate that 
halofuginone is an effective therapy for the treatment of bone metastases, through 
multiple actions that include inhibition of TGFβ and BMP-signaling.
Halofuginone blocked TGF-β-signaling in MDA-MB-231 and PC3 cells showed by 
inhibition of TGF-β–induced Smad-reporter, phosphorylation of Smad-proteins, and 
expression of TGF-β-regulated metastatic genes. Halofuginone increased inhibitory 
Smad7-mRNA and reduced TGF-β-receptor II protein. Proline supplementation but not 
Smad7-knockdown reversed halofuginone-inhibition of TGF-β-signaling. Halofuginone 
also decreased BMP-signaling. Treatment of MDA-MB-231 and PC3 cells with 
halofuginone reduced the BMP-Smad-reporter (BRE)4, Smad1/5/8-phosphorylation 
and mRNA of the BMP-regulated gene Id-1. Halofuginone decreased immunostaining 
of phospho-Smad2/3 and phospho-Smad1/5/8 in cancer cells in vivo.
Furthermore, halofuginone decreased tumor-take and growth of orthotopic-
tumors. Mice with breast or prostate bone metastases treated with halofuginone had 
significantly less osteolysis than control mice. Combined treatment with halofuginone 
and zoledronic-acid significantly reduced osteolytic area more than either treatment 
alone. Thus, halofuginone reduces breast and prostate cancer bone metastases in 
mice and combined with treatment currently approved by the FDA is an effective 
treatment for this devastating complication of breast and prostate-cancer.
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INTRODUCTION
Despite the improvement in breast and prostate 
cancer treatment, 80 percent of the patients with 
advanced disease will develop bone metastases [1, 
2]. The consequences of bone metastases are often 
devastating, and once tumors metastasize to bone, they are 
incurable and cause severe pain, fractures, spinal nerve 
compression and paralysis [3]. Cancer cells produce bone-
resorbing factors leading to increased bone destruction. 
As a consequence, growth factors such as transforming 
growth factor (TGF-β) [4], bone morphogenetic proteins 
(BMPs) and others are released from the mineralized bone 
matrix. In turn, these factors increase tumor production 
of pro-angiogenic and pro-osteolytic factors establishing 
a feed-forward cycle, responsible for tumor growth and 
invasiveness in bone [5, 6]. TGF-β is a main regulator 
of this feed-forward cycle of bone metastasis [7, 8]. It 
stimulates the tumor production of bone-active factors 
(PTHrP, IL-11, ET-1) and prometastatic factors (VEGF, 
CXCR4, CTGF, MMPs), which disrupt normal bone 
remodeling and promote invasion, angiogenesis, and 
homing of tumor cells to bone [9].
Preclinical studies have shown that blockade of 
TGF-β signaling, using small molecule inhibitors of 
TGF-β receptor I kinase activity, reduced melanoma 
and breast cancer bone metastasis and prolonged mouse 
survival [10-12]. A neutralizing pan-TGF-β antibody 
reduced tumor burden and osteolytic lesions in a mouse 
model of bone metastasis [13], and overexpression of 
TGF-β-signaling inhibitor Smad7 in a mouse model 
delayed the establishment and the growth of melanoma 
bone metastases [14, 15].
Halofuginone is a natural product derivative that 
inhibits TGF-β signaling [16, 17], activates the amino 
acid starvation response [18] and has antiangiogenic 
and antiproliferative properties. Halofuginone has 
completed phase I and II clinical trials for the treatment of 
advanced solid tumors and HIV-related Kaposi’s sarcoma 
respectively [19, 20]. We and others have shown that 
halofuginone reduced metastasis and cancer progression in 
different models [21-24]. However its effects in breast and 
prostate cancer bone metastases have not been described. 
We hypothesized that halofuginone would be effective 
against breast and prostate cancer bone metastases and 
that combining halofuginone with the osteoclast inhibitor 
zoledronic acid, an FDA-approved treatment for bone 
metastases, would have additional efficacy against bone 
metastases.
Here, we tested the therapeutic potential of 
halofuginone to prevent breast and prostate cancer bone 
metastases. We explored its actions on TGF-β signaling 
and report for the first time that halofuginone inhibits BMP 
signaling. Finally we evaluated whether halofuginone 
combined with zoledronic acid was more effective than 
either drug alone to treat metastases to bone.
RESULTS
Halofuginone reduces breast and prostate cancer 
bone metastases in mice
We evaluated the potential of halofuginone to treat 
breast and prostate cancer bone metastasis in a murine 
model of bone metastasis. High (5μg/mouse) and low 
doses (1μg/mouse) of halofuginone significantly reduced 
osteolytic lesion area compared to mice treated with PBS, 
when measured on radiographs (Figure 1A and 1C) and 
confirmed by histomorphometric analysis of the tumor 
area (Figure 1B and 1D). The number of osteoclasts at 
the tumor-bone interface was reduced in mice treated with 
halofuginone in a dose-dependent manner (Figure 1E).
Similar results were obtained using a prostate 
cancer bone metastasis model. Male nude mice were 
inoculated with PC3 prostate cancer cells and treated with 
halofuginone. As seen in the breast cancer bone metastases 
model, halofuginone (5μg/mouse) significantly reduced 
the osteolytic area and tumor burden compared to mice 
treated with vehicle (Figure 1F–1I). Osteoclast numbers at 
the tumor-bone interface were also significantly decreased 
(Figure 1J).
Halofuginone inhibits TGF-β signaling
To understand the mechanism by which 
halofuginone inhibits bone metastases, we analyzed its 
effects on breast and prostate cancer cells transfected 
with pGL3-luc plasmid expressing firefly luciferase 
either constitutively or with a TGF-β-responsive reporter 
(CAGA)9-luc. Halofuginone decreased TGF-β–induced 
promoter activity in MDA-MB-231 and PC3 cancer cells 
in a dose-dependent manner (Figure 2A and 2B) while did 
not have any effect on the firefly luciferase constitutively 
active construct (Supplementary Figure 1). Next, we 
studied the TGF-β–induced phosphorylation of Smad2 
and 3 proteins in cancer cells treated with halofuginone 
at different time points (1, 4 and 12h). Halofuginone 
treatment decreased Smad2 and Smad3 phosphorylation 
after 4 and 12h of treatment and as early as 1h for Smad3. 
Levels of total Smad2 and 3 were unchanged (Figure 2C). 
We then examined whether halofuginone could decrease 
the expression of TGF-β–induced genes that promote bone 
metastases [9]. TGF-β treatment alone increased mRNA 
levels of PTHrP, CXCR4 and CTGF in breast and prostate 
cancer cells. In contrast, cells treated with TGF-β in the 
presence of halofuginone had significantly lower levels of 
TGF-β-regulated mRNAs (Figure 2D and 2E).
Halofuginone inhibits BMP signaling
Bone morphogenetic proteins (BMPs) have been 
associated with cancer risk, and are also members of the 
TGF-β superfamily [27]. Therefore, we tested the effect 
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Figure 1: Halofuginone reduces breast and prostate cancer bone metastases. (A, F) Representative radiography of the 
hindlimbs of female and male nude mice inoculated with MDA-MB-231 (A-E) or PC3 cells (F-J), respectively, and treated with PBS 
or halofuginone (Hfg), 1 or 5µg/mouse/day for up to 5 weeks. Arrows indicate osteolytic lesions. (B, G) Representative histology of 
tibias with bone metastases. (C, H) Osteolytic area (mm2) measured on radiographs of hindlimbs of mice with bone metastases. * P<0.05 
vs Hfg 1 or 5µg/mouse using one-way ANOVA with Bonferonni’s posttest. (D, I) Tumor burden area (mm2) measured by quantitative 
histomorphometry. (E, J) Osteoclast number at tumor-bone interface of hindlimbs of mice with bone metastases. *P<0.05 vs PBS using 
One-way ANOVA with Bonferroni’s post-test.
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of halofuginone on BMP signaling. We transfected breast 
and prostate cancer cells with a plasmid expressing firefly 
luciferase under the control of a BMP responsive reporter, 
(BRE)
4
. Cells were treated with BMP4 in the presence 
or absence of halofuginone. Halofuginone treatment 
significantly reduced the activity of BMP signaling 
responsive promoter in a dose-response manner (Figure 
3A). In addition, we analyzed halofuginone effects on the 
mRNA expression of ID-1, a BMP-specific target gene. 
Only BMP4 increased ID-1 expression in MDA-MB-231 
and PC3 cells, not a treatment with TGF-β (Figure 3B). 
Halofuginone reduced mRNA expression of ID-1 induced 
by BMP4 treatment (Figure 3B). Next we tested the effect 
of halofuginone on the activation of BMP-specific Smads. 
Halofuginone inhibited the phosphorylation of Smad1/5/8 
in both MDA-MB-231 and PC3 cells, while total Smad1 
was unchanged (Figure 3C). These results show for the 
first time that halofuginone inhibits BMP signaling.
Halofuginone reduces intracellular mediators of 
TGF-β and BMP signaling in vivo
We asked whether halofuginone also reduced TGF-β 
and BMP signaling at sites of bone metastases. We used 
immunostaining of phosphorylated Smad2/3 to assess 
TGF-β signaling activity in bone metastases from MDA-
MB-231 breast cancer cells in mice treated or not treated 
with halofuginone. Similarly to Kang et al., we found 
that phospho-Smad2/3 mainly localized in the nuclei of 
cancer cells closer to the tumor-bone interface indicating 
a gradient of TGF-β released from the bone matrix [4]. 
There was a significant reduction of nuclear phospho-
Smad2/3 in cancer cells when mice were treated with 
halofuginone, showing a decrease of TGF-β signaling 
activity (Figure 4A and 4C). Similarly, BMP signaling 
activity in vivo was assessed by immunostaining using 
an antibody against phosphorylated Smad1/5/8. In mice 
treated with halofuginone (1 and 5µg/day) there was an 
inhibition of BMP signaling activity in breast cancer cells 
in bone as measured by phospho-Smad1/5/8-positive 
nuclei (Figure 4B and 4C).
Knockdown of Smad7 does not prevent 
inhibition of TGF-β signaling by halofuginone
Halofuginone induces Smad7 mRNA expression, 
a negative regulator of TGF-β signaling [17]. Inhibition 
of TGF-β signaling by halofuginone could be mediated 
by Smad7. We tested whether knockdown of Smad7 
could overcome TGF-β signaling inhibition caused by 
halofuginone. TGF-β increased Smad7 mRNA in MDA-
MB-231 and PC3 cells. Halofuginone treatment alone 
induced Smad7 mRNA mainly on MDA-MB-231 cells, 
however combined with TGF-β enhanced the increase 
of Smad7 in both breast and prostate cell lines (Figure 
5A). We used a combination of 2 siRNAs to decrease 
Smad7 mRNA by 80% in the presence of TGF-β and 
halofuginone, when compared to untransfected cells or to 
cells transfected with a GFP siRNA control (Figure 5B). 
Real-time PCR of MDA-MB-231 samples showed that 
Smad7 knockdown did not prevent the decrease of TGF-β 
regulated genes (collagen α1, PTHrP, CXCR4, CTGF) 
caused by halofuginone (Figure 5C). Therefore Smad7 
does not mediate the inhibition of TGF-β signaling by 
halofuginone in MDA-MB-231.
Halofuginone inhibits TBRII translation
A second mechanism proposed for TGF-β signaling 
inhibition by halofuginone is through down-regulation 
of TGF-β receptor II (TBRII) [17]. Figure 6A shows that 
halofuginone treatment of breast and prostate cancer cells 
reduces TBRII protein levels, while TGF-β receptor I 
(TBRI) protein levels were unaffected. Transfection of 
MDA-MB-231 with plasmids expressing TBRII and TBRI 
alone or in combination did not reverse halofuginone-
induced inhibition of TGF-β signaling (Figure 6B). 
Besides, Western blot analysis showed that exogenous 
Flag-TBRII protein was not detected in MDA-MB-231 
treated with halofuginone (Figure 6C). RT-PCR indicated 
that halofuginone did not have any effect on TBRII mRNA 
suggesting that halofuginone effect on TBRII is post-
transcriptional.
We investigated first whether halofuginone increases 
TBRII degradation. Neither the proteasome inhibitors 
MG132 and bortezomib, nor chloroquine, which inhibits 
lysosomal degradation, prevented the halofuginone-
induced decrease of TBRII (Figure 6E). Next, we treated 
our cells with cycloheximide to stop de novo protein 
synthesis and assayed TGF-β receptor degradation by 
Western blot. After addition of cycloheximide, TBRII was 
quickly degraded and addition of halofuginone did not 
increase the degradation rate of TBRII (Figure 6F). TBRI 
appeared more stable, and its levels remained unchanged 
after 12h of treatment (Figure 6F). To test whether 
halofuginone affects TBRII synthesis, we treated cells with 
cycloheximide overnight to stop de novo protein synthesis 
and eliminate endogenous TBRII. Cycloheximide was 
then removed and new TBRII protein was detected 2h 
later. Addition of halofuginone completely prevented the 
synthesis of TBRII protein (Figure 6G). These results 
show that halofuginone inhibits TBRII protein translation.
Proline reverses inhibitory effects of 
halofuginone on TGF-β signaling
Keller et al, have shown that halofuginone is a 
potent competitive inhibitor of the glutamyl-prolyl-
tRNA-synthetase that adds proline to its tRNA [28]. 
Accumulation of amino acid-free tRNA triggers the amino 
acid response (AAR) and the phosphorylation of the 
translation initiation factor EIF2α. Halofuginone induced 
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Figure 2: Halofuginone inhibits TGF-β signaling in MDA-MB-231 and PC3 cancer cells. (A, B) Dual luciferase assay-
(CAGA)9 reporter of MDA-MB-231 & PC3 cells treated with Hfg, followed by TGF-β (5ng/ml) for 24h. (C) Western blot analysis of 
breast and prostate cancer cells treated with 200nM Hfg for 1, 4 or 12h before adding TGF-β (5ng/mL, 30min) to assess Smad2 and Smad3 
phosphorylation. (D, E) Expression of PTHrP, CXR4 and CTGF mRNAs in MDA-MB-231 and PC3 cells pretreated with Hfg (200nM) 
and treated or not with TGF-β (5ng/mL) and for 24h using quantitative real-time RT-PCR. *P<0.05 vs PBS using One-way ANOVA with 
Bonferroni’s post-test.
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Figure 3: Halofuginone inhibits BMP signaling. (A) Dual luciferase assay-(BRE)
4
 promoter of MDA-MB-231 & PC3 cells treated 
with Hfg followed by BMP4 (50ng/ml) for 24h. (B) Expression of ID1 mRNA in MDA-MB-231 and PC3 cells pretreated with Hfg 
(200nM) and treated or not with BMP4 (50ng/mL) and for 24h by qRT-PCR. (C) Western blot analysis for Smad1/5/8 phosphorylation of 
breast and prostate cancer cells pretreated with 200nM Hfg for 4h followed by BMP4 (50ng/mL) for 30min. *P<0.05 vs PBS using One-
way ANOVA with Bonferroni’s post-test.
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Figure 4: Halofuginone reduces TGF-β and BMP signaling in vivo. Immunohistochemistry of (A) phospho-Smad2/3 and (B) 
phospho-Smad1/5/8 tumor tissue sections from limbs of mice with bone metastases caused by MDA-MB-231 cells and treated with Hfg 
(1μg/5μg) or PBS. (C) Quantitative analysis of nuclei positives for phosphorylated Smad2/3 or Smad1/5/8 in bone metastases. *P<0.05 vs 
PBS using One-way ANOVA Bonferroni’s post-test.
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Figure 5: Knockdown of Smad7 does not prevent inhibition of TGF-β by halofuginone. (A) Smad7 mRNA levels analyzed 
by qRT-PCR in MDA-MB-231 and PC3 cells treated with 200nM Hfg for 4h followed by 5ng/ml TGF-β for 60 min. (B) MDA-MB-231 
cells transfected or not transfected with siRNA against Smad7 or GFP as a control. Smad7 mRNA was quantified by qRT-PCR. (C) 
Quantification of mRNA levels of Collagen α1 and pro-metastatic genes PTHrP, CXCR4 and CTGF in MDA-MB-231 cells with or without 
a knockdown of Smad7 or TGF-β (5ng/mL) and Hfg (200nM) for 24h. *P<0.05 vs PBS, § P<0.05 vs Hfg using One-way ANOVA with 
Bonferroni’s post-test.
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Figure 6: Halofuginone inhibits TBRII synthesis by activating the amino acid starvation response. (A) Western blot 
analysis of MDA-MB-231 & PC3 cells for TGF-β type I and II receptors (TβRI and TβRII) after a 24h-treatment with 5ng/ml TGF-β and 
200nM Hfg. (B) Dual luciferase assay-(CAGA)9 reporter of MDA-MB-231 & PC3 cells transfected or not with TβRI, TβRII or both, 24h 
later cells treated with 200nM Hfg and 5ng/ml TGFβ for 24h. (C) Western blot of MDA-MB-231 cells transfected with pRK5-TβRII-Flag 
plasmid treated with vehicle or 200nM Hfg and 5ng/ml TGF-β. (D) TBRII mRNA levels analyzed by qRT-PCR in MDA-MB-231 cells 
treated with 200nM Hfg for 4h followed by 5ng/ml TGF-β for 30 min for 24 hrs. (E) MDA-MB-231 cells treated with 5μM MG132, 
1μM bortezomib or 10μM chloroquine for 24h lysed and tested for TBRII, TBRI, Tubulin and Ubiquitin. (F-G) Time course of TGF-β 
receptor analysis, MDA-MB-231 cells treated with 1μM cycloheximide en the presence of 200nM Hfg (F) or pretreated with cycloheximide 
overnight followed by 200nM Hfg (G). (H) Proline (1μM) was added to the media of MDA-MB-231 cells treated with Hfg or 5ng/ml 
TGF-β alone or with 100nM Hfg. (I, J) Western blot of MDA-MB-231 cells treated with 100nM Hfg alone or with 1μM proline for 4h, 
to detect Phospho-EIF2 and EIF2. J) After 30 min of TGF-β treatment, Phospho-Smad2 and Smad2 proteins are showed. All western blot 
experiments were normalized with tubulin. * P<0.05 vs PBS, **P<0.05 vs TGF-β. One-way ANOVA Bonferroni’s post-test.
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the phosphorylation of EIF2α, which was prevented by the 
addition of proline (Figure 6H).
We therefore examined whether proline 
supplementation would reverse the inhibitory effects 
of halofuginone on TBRII. Proline reversed TBRII 
suppression in cells treated with halofuginone for 24h in 
the presence or absence of TGF-β (Figure 6I). Inhibition 
of Smad2 phosphorylation by halofuginone was also 
rescued by the addition of proline (Figure 6J) indicating 
that halofuginone inhibits TGF-β signaling is mediated by 
the AAR.
Halofuginone reduces orthotopic tumor growth 
and in combination with zoledronic acid 
enhances inhibition of bone metastasis
To investigate the effects of halofuginone on 
primary tumors, we inoculated breast cancer cells in 
the mammary fat pad (MFP) of female nude mice and 
treated them with two different doses of halofuginone (1 
or 5μg/mouse/day). Mice treated with the high dose of 
halofuginone showed a significant reduction in the tumor 
volume and tumor weight compared to the control mice. 
Low dose halofuginone treatment did not affect the growth 
of MFP tumors (Figure 7A and 7B).
We next evaluated combined treatment with 
halofuginone and zoledronic acid, an inhibitor of bone 
resorption approved by the FDA for the treatment of bone 
osteolysis. We inoculated female nude mice with breast 
cancer cells and treated them during 4 weeks with PBS 
as a placebo or with halofuginone (5μg/mouse/day) or 
zoledronic acid (5μg/kg/3X per week) alone or combined. 
Halofuginone and zoledronic acid treatments alone 
significantly reduced to a similar extent osteolytic area 
on radiographs (Figure 7C and 7E). Combined treatment 
further decreased the area of osteolysis when compared to 
mice treated with either agent alone. Histomorphometric 
analysis of the tumor burden confirmed that halofuginone 
and zoledronic acid alone decreased the tumor burden 
area when compared to PBS-treated-mice and that the 
combined treatment was more efficient at decreasing 
tumor area than halofuginone alone (Figure 7D). Analysis 
of TRAP+ osteoclasts showed that halofuginone and 
zoledronic acid alone or combined significantly reduced 
osteoclast number (Figure 7F). Total bone area was not 
affected by any of the treatments (Figure 7F).
DISCUSSION
Bone metastasis is a very frequent complication 
of patients with advanced breast and prostate cancer. 
Preclinical models have demonstrated that blockade of 
TGF-β signaling is effective to prevent bone metastasis. 
In this study, we found that halofuginone reduced breast 
and prostate cancer metastases in vivo and this reduction 
was enhanced by combination with zoledronic acid in 
a mouse model of breast cancer bone metastasis. We 
previously demonstrated the potential of halofuginone to 
reduce bone metastasis in a mouse model of melanoma 
[24]. In a similar manner, halofuginone significantly 
reduced tumor burden and osteolytic lesion area in both 
models of breast and prostate cancer bone metastasis. This 
inhibition was accompanied by a reduction of the number 
of osteoclasts at the tumor-bone interface. Halofuginone 
inhibited cell proliferation of breast and prostate cancer 
cells in vitro (data not shown) and reduced tumor growth 
in mice at the orthotopic site, showing that its effects are 
not limited to bone; unlike the effects of other TGF-β 
inhibitors, including SD208 and overexpression of Smad7 
in melanoma cells [12, 15]. The effects of halofuginone 
against bone metastases are consistent with an inhibition 
of TGF-β signaling in vivo, as shown by the decrease of 
phosphorylated Smad2/3 in the nuclei of cancer cells, and 
a subsequent decrease of TGF-β-regulated prometastatic 
genes in tumor cells. However we can not exclude that 
halofuginone has direct effect on bone cells such as 
osteoclasts and osteoblasts.
In vitro studies confirmed that halofuginone 
inhibited TGF-β signaling in breast and prostate cancer 
cells as shown by: a) reduction of TGF-β receptor II 
protein, b) inhibition of Smad intracellular mediators, c) 
inhibition of a TGF-β-responsive reporter and d) reduction 
of prometastatic TGF-β-regulated genes.
We explored the effects of halofuginone on bone 
morphogenetic protein (BMP) signaling, since BMPs 
are members of the TGF-β superfamily. BMPs have 
been linked to cancer predisposition and are aberrantly 
expressed in multiple malignancies [27, 29]. The role of 
BMPs in cancer is still emerging and vary from one BMP 
ligand and tumor type to another, resembling the dual role 
of TGF-β as a suppressor of tumorigenesis and promoter 
of metastasis [30, 31]. In vitro, breast and prostate cancer 
cells treated with halofuginone showed inhibition of BMP 
signaling demonstrated by inhibition of BMP-responsive 
promoter, inhibition of Phospho-Smad1/5/8 and reduction 
of ID1, a regulator of cancer cell growth and migration 
[32]. Consistent with the in vitro data, tumors of mice with 
breast cancer bone metastasis had a reduction in phospho 
SMAD1/5/8-positive nuclei, suggesting an inhibition of 
BMP signaling in the bone metastatic microenvironment 
of mice treated with halofuginone. Whether halofuginone 
effects on TGFβ and BMP signaling are correlated or 
independent of each other needs to be determined.
Although halofuginone inhibition of TGF-β 
signaling has been described before [17, 33], its precise 
mechanisms of action remain unknown. It was proposed 
that the inhibition of TGF-β signaling by halofuginone 
is mediated by induction of Smad7, a negative regulator 
of TGF-β signaling, and down regulation of TGF-β 
receptor II (TβRII) [17]. In breast and prostate cancer 
cells, halofuginone increased Smad7 mRNA; however 
knockdown of Smad7 did not prevent halofuginone 
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Figure 7: Halofuginone reduces orthotopic tumor growth and in combination with zoledronic acid enhances inhibition 
of bone metastases. (A) Volume and (B) weight of MDA-MB-231 tumors in the mammary fat pad of female nude mice treated with 
halofuginone (Hfg, 1 or 5μg/mouse) or PBS. (C) Representative radiography of hind limbs of female nude mice inoculated with MDA-
MB-231 cells and treated with PBS, Hfg (5μg/mouse/day), zoledronic acid (ZA, 5μg/kg/3x per wk) or Hfg and ZA combined. (D) 
Representative images of tumor burden and histomorphometric quantification. (E) Quantification of osteolytic area on radiography. (F) 
Quantification of the osteoclast number at the tumor bone interface and (G) Total bone area *P<0.05 vs PBS, § P<0.05 vs Hfg using One-
way ANOVA with Bonferroni’s post-test.
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inhibition of TGF-β-regulated genes. When studying the 
regulation of TBRII, TGFβ itself caused a significant 
reduction in the amount of TBRII protein, while co-
treatment with halofuginone appears to enhance that 
effect. Halofuginone also prevented the expression of 
endogenous as well as exogenous TBRII protein without 
affecting mRNA levels, suggesting that halofuginone 
effects are post-transcriptional. Proteasome and lysosome 
inhibitors, and a cycloheximide-chase assay suggested 
that halofuginone does not regulate TBRII degradation. 
Analysis of newly synthesized TBRII protein in cells 
confirmed that halofuginone prevents TBRII expression 
at the translational level. Sundrud et al recently showed 
that halofuginone activates the amino acid starvation 
response pathway and inhibits differentiation of TH17 
cells [18]. Amino acid restriction results in accumulation 
of amino acid-free tRNAs and the subsequent inhibition 
of the translation machinery. Halofuginone triggers the 
amino acid starvation pathway by inhibiting prolyl tRNA 
synthase activity, which can be reversed by the addition 
of exogenous proline [28]. Proline addition effectively 
prevented the halofuginone-induced activation of the 
AAR pathway as shown by the decreased phosphorylation 
of EIF2. Proline also rescued the inhibition of TBRII 
synthesis caused by halofuginone and restored TGF-β 
signaling pathway. These results indicate for the first time 
that halofuginone inhibits TGF-β signaling by activating 
the amino acid starvation pathway that stops protein 
translation and results in the quick depletion of TBRII in 
cancer cells. Whether halofuginone activates the amino 
acid starvation pathway in cancer cells at the site of bone 
metastases in our mouse model remains to be determined.
Lastly, we evaluated the anti-tumor efficacy of 
halofuginone in combination with the bisphosphonate, 
zoledronic acid, in a mouse model of breast cancer bone 
metastasis. Bisphosphonates are a palliative therapy 
available for cancer patients with skeletal-related 
symptoms. Nitrogen-containing bisphosphonates block 
osteoclastic bone resorption by inhibiting the mevalonate 
pathway, leading to osteoclast apoptosis [34]. They may 
also have direct anti-tumor effects, including inhibition 
of tumor growth, tumor invasion and anti-angiogenic 
activity [35, 36]. Bisphosphonates reduce the availability 
of TGF-β to tumor cells through inhibition of bone matrix 
destruction [4, 37]. In our study, combined treatment with 
halofuginone and zoledronic acid decreased the tumor 
burden and osteolytic lesion area in mice more effectively 
than either treatment alone. The combined treatment was 
associated with a reduction of the osteoclast number at 
the tumor-bone surface. The beneficial effects of the 
combined therapy may be due to the inhibition of TGF-β 
signaling and direct effects on tumor of both molecules, 
but the precise mechanism remains to be established. 
Interestingly, we also observed slightly less trabecular 
bone in mice treated with the combined treatment 
compared to mice treated with zoledronic acid alone. 
Considering that zoledronic acid efficiently inhibited bone 
resorption in our model, the lower amount of trabecular 
bone suggests that halofuginone also has an effect on bone 
formation. This would be consistent with the inhibition 
of BMP signaling induced by halofuginone since BMPs 
are a main regulator of bone formation. Experiments to 
determine the effect of halofuginone on bone formation in 
normal bone are ongoing.
In summary, halofuginone reduces breast and 
prostate cancer bone metastasis and inhibits multiple 
targets including TGF-β and BMP signaling pathways 
as shown by inhibition of TGF-β and BMP regulated 
prometastatic genes. It also has direct effects on the 
growth of cancer cells. The combination of halofuginone 
and zoledronic acid was more effective to decrease 
osteolytic bone lesions, suggesting that patients with 
bone metastasis may be treated with lower dose of 
zoledronic acid when in combination with halofuginone 
reducing the risk of side effects associated with 
bisphosphonates.
MATERIALS AND METHODS
Cell cultures and reagents
MDA-MB-231 breast and PC3 prostate cancer 
cells (both from the American Type Culture Collection) 
were cultured in DMEM or RPMI media, respectively, 
supplemented with 10% FBS and antibiotics. All cells 
were grown at 37°C with 5% CO2 in a humidified 
chamber. Halofuginone (dl-trans-7-bromo-6-chloro-3-[3-
(3-hydroxy-2piperidyl) acetonyl]-4(3H)-quinazolinone 
hydrobromide) was a gift from Intervet Innovation 
GmbH. For in vitro studies, halofuginone stock solutions 
(2mg/ml) were prepared in lactic acid buffer (0.44M, pH 
4.3) and stored at -20°C [24]. For in vivo experiments, 
halofuginone (1 or 5μg/0.1 ml) was resuspended in PBS. 
Zoledronic acid (Novartis) stock solution was prepared in 
0.15M NaCl. Recombinant human TGF-β1 and BMP-4 
were purchased from R&D Systems Inc. pRK5-TGFRII-
Flag plasmid (31719) was obtained from Addgene.
Western blot analysis
Cells were pretreated with halofuginone (200nM) 
for 4h followed by TGF-β (5ng/ml) or BMP4 (200ng/ml) 
for 30min for phospho-Smad protein analysis, and 24h 
for TGF-β receptor analysis. Proteins were separated by 
SDS-PAGE and transferred onto a Hybond™-P membrane 
(GE Healthcare Life Sciences). Membranes were blocked 
in TBST-milk (5%) for 1h, incubated overnight with 
primary antibody and for 1h with peroxidase-conjugated 
secondary antibody. Protein detection used Western 
Chemiluminescent HRP substrate (EMD Millipore). 
Antibodies against Smad2/3, Smad1, phospho-Smad2/3, 
phospho-Smad1/5/8, EIF2α and phospho-EIF2α were 
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purchased from Cell Signaling. Anti-α-tubulin (Sigma) 
was used for normalization.
Gene expression analysis
Cells were pretreated with halofuginone (200nM) 
for 4h followed by TGF-β (5ng/ml) or BMP4 (200ng/ml) 
for 24h in basal media-FBS (0.2%). Cells were lysed in 
Trizol (Invitrogen). Total RNA was isolated using RNeasy 
kit (Qiagen) and reverse transcribed using Superscript II 
(Invitrogen). qRT-PCR was performed using QuantiTect 
SYBR Green PCR Kit (Qiagen) and processed in a 
MyiQTM Single-Color Real Time PCR detection system 
(BioRad) for 40 cycles (95°C for 15 sec/58°C for 30 
sec/72°C for 30sec) after an initial 15min incubation at 
95°C. Primers were optimized for qRT-PCR amplification 
efficiency 100±5% (for sequences see Supplemental 
Material). Data of triplicates samples were analyzed by 
the ΔΔCt method [25].
Dual-luciferase assay
For TGF-β-responsive promoter studies, cells 
were transfected with pGL3-luc constructs (Promega) 
expressing firefly luciferase either constitutively or under 
the control of a Smad3/Smad4-specific promoter (CAGA)9 
[26]. To study TGF-β receptors, cells were cotransfected 
with (CAGA)9 promoter, pcDNA3-TBRI and pcDNA3-
TBRII (kind gift from Dr. J. Massague, Memorial Sloan-
Kettering Cancer Center) alone or combined. For BMP 
studies, cells were transfected with a pGL3 plasmid 
containing the (BRE)
4
 luciferase reporter based on the 
mouse Id1 promoter and responsive to BMP (generously 
provided by Dr Peter Ten Dijke). phRL-CMV plasmid 
constitutively expressing Renilla luciferase (Promega) 
was used for normalization in all analyses. Twenty-four 
hours later, cells were treated with different concentrations 
of halofuginone (50-500nM) for 4h in basal medium 
supplemented with 0.2% FBS, followed by TGF-β 
(5ng/ml) or BMP4 (50ng/ml) for 24h. Cells were lysed 
using Passive Lysis Buffer (Promega), and analyzed for 
luciferase activity using the Dual-Luciferase Reporter 
Assay System (Promega) and a Synergy MX plate reader 
(Biotek).
Knockdown of Smad7
MDA-MB-231 cells were transfected with a mix 
of siRNAs designed against Smad7 (GeneSolution) to 
maximize knockdown efficiency (for sequences see 
Supplemental Material). Cells at 80% of confluence were 
transfected with 20nM of each siRNAs-Smad7. Twenty-
four hours later, cells were pretreated with halofuginone 
(200nM) for 4h in basal media supplemented with 0.2% 
FBS, followed by TGF-β (5ng/ml) for 24h. Cells were 
lysed and total RNA analyzed by qRT-PCR for Smad7 and 
TGF-β regulated genes.
Protein degradation and synthesis assay
MDA-MB-231 cells were treated with proteasome 
inhibitors, MG132 (5μM) and Bortezomib (1μM), or 
lysosome inhibitor, chloroquine (10μM), for 24h, in the 
presence or absence of 200nM halofuginone. For protein 
degradation, cells were treated with cycloheximide (1μM) 
alone or with halofuginone (100nM) for 1-12h. To evaluate 
protein synthesis, cells were treated with cycloheximide 
(1μM) overnight, next day cells were washed twice 
with PBS followed by vehicle or halofuginone (100nM) 
treatment for 1-8h. Cells were lysed and Western blot 
analysis for TGF-β receptors was performed.
Proline rescue experiments
MDA-MB-231 cells were pretreated with 
halofuginone (100nM) alone or with 1μM proline (Sigma 
Aldrich) for 4h in DMEM media. Followed by TGF-β 
(5ng/ml) treatment in DMEM (0.2% FBS), for 30min 
for phospho-Smad protein analysis or 24h for TGF-β 
receptors. For phospho-EIF2α and EIF2α protein analysis, 
cells were treated with halofuginone (100nM) alone or 
with proline for 4h. Cells lysates were assayed by Western 
blot.
Animal studies
Animal experiments were performed at the 
University of Virginia in Charlottesville, Virginia and 
Indiana University. Animal protocols were in accordance 
with the national and international guidelines and 
approved by the respective Institutional Animal Care and 
Use Committees.
Mammary fat pad tumor model
MDA-MB-231 cells (106 cells per 100μl of PBS) 
were inoculated into the upper mammary fat pad of 5 
weeks-old female nude mice. When palpable tumors were 
detected, the mice were divided into 3 groups (n=10) 
to receive either halofuginone (1 or 5μg/mouse/day) 
or PBS treatment daily by i.p. injection. Tumor volume 
was measured with a caliper three times per week and 
calculated from the formula: tumor volume = 4/3 π x L/2 
(W/2)2, where L and W represent mid-axis length and 
width, respectively.
Bone metastasis mouse model
Intracardiac inoculation of tumor cells was 
performed as previously described [14]. Briefly, 
MDA-MB-231 or PC3 cancer cells were trypsinized 
and resuspended in PBS to a final concentration of 
106 cells per milliliter. Five-weeks old female or male 
mice (n=12) were anesthetized and inoculated into the 
left ventricle with MDA-MB-231 or PC3 cells 105 in 
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100µl/mouse. Halofuginone (1 or 5μg/mouse), or PBS 
were administered daily by i.p. injection two days prior 
to tumor cell inoculation and continued throughout 
the experiment. The development of osteolytic lesions 
was followed with a Faxitron MX-20 X-ray machine 
(Faxitron X-ray Corporation). Lesion area was confirmed 
with histology and quantified using MetaMorph analysis 
system software (Universal Imaging Corporation). 
Combined treatment with halofuginone and zoledronic 
acid followed similar experimental approach, 
halofuginone (5μg/mouse) and PBS were administrated 
daily by i.p. injection while zoledronic acid (5μg/kg) 
was administered three times per week s.c. throughout 
the experiment.
Bone histology & histomorphometry
Bones from the forelimbs and hindlimb were 
collected upon euthanasia, fixed in 10% formalin 
for 48h, decalcified in 10% EDTA for 2 weeks, and 
embedded in paraffin. Tissue sections from tibia and 
femur were cut using an automated Microm HM 355S 
microtome (Thermo Fisher Scientific) and stained with 
hematoxylin and eosin (H&E) or for TRAP (tartrate-
resistant acid phosphatase) activity. Bright field images 
were captured using a Q-Imaging Micropublisher 
Cooled CCD color digital camera (Vashaw Scientific 
Inc., Washington, DC, USA) on a Leica DM 
LB compound microscope (Leica Microsystem, 
Bannockburn, IL, USA). Histomorphometric analysis 
of tumor burden area, defined as area of bone occupied 
by cancer cells, and total bone area was performed 
using BIOQUANT OSTEO software (Image Analysis 
Corporation). Osteoclast numbers at the tumor bone 
interface were quantified on TRAP-stained sections of 
femur and tibia at 400X magnification.
Immunohistochemistry
Immunohistochemical analysis was performed on 
decalcified paraffin-embedded tissue sections. Tissue 
sections were deparaffinized and treated with 3% hydrogen 
peroxide and trypsin for antigen retrieval (Invitrogen). 
Blocking of non-specific binding sites was done using 
normal goat serum (10%) and an avidin/biotin blocking 
kit (Vector Laboratories) before probing using antibodies 
against phospho-Smad2/3 or phospho-Smad1/5/8 (Cell 
Signaling) at 1:500 dilution. After incubation with a biotin-
conjugated anti-rabbit antibody (EMD Millipore) and a 
streptavidin-peroxidase conjugate (Vector Laboratories), 
slides were stained using 3,3-diaminobenzidine substrate 
kit (Vector Laboratories) and counterstained with 
hematoxylin. The percentage of phospho-Smad positive 
nuclei per field was quantified. Five fields (200X) per 
animal were analyzed.
Statistical analysis
Results are expressed as mean ± SEM. Samples 
were analyzed in triplicate. Differences between groups 
were analyzed by one-way ANOVA or two-way ANOVA 
followed by Bonferroni’s post-test. All the data were 
analyzed using Graphpad Prism v4.0 software (GraphPad 
Sofware, Inc). P<0.05 was considered significant.
Supplementary information
A single pdf includes Supplementary Methods for 
the design of real-time PCR primers and siRNAS Smad7 
sequences, and one Supplementary Figure showing the 
halofuginone effect in a CMV constitutive activated 
promoter.
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